After finishing at $5.43 in the prior trading day, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) closed at $5.37, down -1.10%. In other words, the price has decreased by -$0.06 from its previous closing price. On the day, 1413899 shares were traded. AUPH stock price reached its highest trading level at $5.56 during the session, while it also had its lowest trading level at $5.34.
Ratios:
Our goal is to gain a better understanding of AUPH by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.99 and its Current Ratio is at 5.50. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.22.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’24 when Greenleaf Peter sold 126,981 shares for $5.60 per share. The transaction valued at 711,094 led to the insider holds 1,522,114 shares of the business.
Robertson Stephen P. sold 57,745 shares of AUPH for $323,372 on Mar 06 ’24. The EVP, General Counsel now owns 443,824 shares after completing the transaction at $5.60 per share. On Mar 06 ’24, another insider, Donley Matthew Maxwell, who serves as the EVP, Ops & Strategy of the company, sold 40,665 shares for $5.51 each. As a result, the insider received 224,064 and left with 584,072 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 786.00M and an Enterprise Value of 533.12M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.42 while its Price-to-Book (P/B) ratio in mrq is 2.04. Its current Enterprise Value per Revenue stands at 3.04 whereas that against EBITDA is -8.46.
Stock Price History:
Over the past 52 weeks, AUPH has reached a high of $12.43, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is 7.32, while the 200-Day Moving Average is calculated to be 8.67.
Shares Statistics:
The stock has traded on average 2.54M shares per day over the past 3-months and 1.79M shares per day over the last 10 days, according to various share statistics. A total of 143.83M shares are outstanding, with a floating share count of 127.57M. Insiders hold about 11.79% of the company’s shares, while institutions hold 36.53% stake in the company. Shares short for AUPH as of Feb 15, 2024 were 16.85M with a Short Ratio of 6.64, compared to 16.39M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.65% and a Short% of Float of 11.69%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.14 for the current quarter, with a high estimate of $0.01 and a low estimate of -$0.2, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.04 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.15 and -$0.34 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is $0.39, with 6 analysts recommending between $0.83 and -$0.14.
Revenue Estimates
6 analysts predict $47.45M in revenue for the current quarter. It ranges from a high estimate of $51.82M to a low estimate of $46M. As of the current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $34.41M, an estimated increase of 37.90% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $232.83M, while the lowest revenue estimate was $207M, resulting in an average revenue estimate of $224.25M. In the same quarter a year ago, actual revenue was $175.51M, up 27.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $288.87M in the next fiscal year. The high estimate is $339.89M and the low estimate is $250M. The average revenue growth estimate for next year is up 28.80% from the average revenue estimate for this year.
